DLBCL: Comparing Treatment Options

Most people with DLBCL start with R-CHOP. This is rituximab plus four chemotherapy drugs, given in repeating cycles over several months. How many cycles, and whether radiation is added at the end, depends on the stage, the risk score and how the disease responds on scanning partway through; limited-stage disease is often treated with fewer cycles than advanced disease. This regimen cures a substantial share of patients. Ask what response and risk factors your team used to confirm R-CHOP is the right starting point for you.

Some people have higher-risk features, including certain MYC and BCL2 gene changes. They may instead be offered Pola-R-CHP. This swaps in a drug called polatuzumab vedotin. A related, distinct lymphoma is called primary mediastinal B-cell lymphoma. It often responds well to a different regimen, dose-adjusted R-EPOCH. The right combination depends on your subtype, cell-of-origin result, and risk score, not just on having DLBCL.

Your team will likely order a scan partway through chemotherapy. This checks how well it is working. Another scan follows after treatment ends. Blood counts are checked often, since chemotherapy can lower them and raise infection risk.

Relapsed or treatment-resistant DLBCL has real options. CD19-directed CAR T-cell therapy uses your own immune cells, reprogrammed in a lab to attack the lymphoma. In trials of refractory disease, about 50% to 60% of people had a complete response. Other chemotherapy combinations, sometimes followed by a stem cell transplant, remain options too. Which path fits depends on how quickly the lymphoma returned and your overall fitness.

R-CHOP has decades of use and a strong track record. But it can cause hair loss, low blood counts, and fatigue. One of its drugs can also cause nerve tingling. Pola-R-CHP adds its own nerve-related side effects. CAR T-cell therapy can work well in hard cases. But it carries real risks. One is cytokine release syndrome, a reaction with fever and low blood pressure. Another is neurologic side effects, such as confusion. Both usually require staying near a specialized treatment center for a few weeks after infusion. This way, side effects can be caught early.

• Was cell-of-origin, MYC, and BCL2 testing done, and how did it shape my plan?
• Why was this specific regimen chosen over the alternatives?
• When is my mid-treatment scan, and what result would change the plan?
• What side effects need same-day contact with the clinic?
• If this does not work, is CAR T-cell therapy or a trial an option for me?

• Call 911 or go to an emergency department if you have had CAR T-cell therapy and you develop a high fever with dizziness or faintness. That combination can mean cytokine release syndrome, which can drop your blood pressure dangerously.
• Call 911 or go to an emergency department if you have had CAR T-cell therapy and you become confused, hard to rouse, or your speech changes, or if you have a seizure. These are the neurologic side effects your team screens for. A caregiver should make this call, since you may not notice it yourself.
• Call 911 or go to an emergency department if your face or neck swells and your breathing becomes hard. A lymphoma mass in the chest can press on the large vein returning blood to the heart.
• Call your lymphoma team immediately, day or night, if the thermometer shows 100.4°F (38°C) or higher, or chills come over you. NCI words its threshold as 100.5°F, so 100.4°F is the lower and safer line; use a lower one still if your team has given you one. Your white cells reach their lowest point roughly one to two weeks after each cycle, and a fever in that window is a medical emergency. It needs urgent assessment and, if infection is suspected, antibiotics started without delay. If you cannot reach the team fast, go to an emergency department and say you are on chemotherapy.
• Call your care team the same day if you bruise without injury, bleed from the gums, or have a nosebleed that will not settle. Chemotherapy also lowers platelets.
• Tell the nurse straight away, during an infusion, if you flush, shiver, feel faint, or get short of breath. Rituximab can cause a reaction while it is running.
• Call your care team within a day or two if a lymph node starts growing quickly again, or drenching night sweats return.
• Call your care team within a day or two if numbness or tingling in your hands or feet gets worse, or you start dropping things. Telling your team early can change the dose before the nerve damage sets.

• National Cancer Institute — Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ).
• National Cancer Institute — Infection and Neutropenia During Cancer Treatment.
• National Cancer Institute — CAR T Cells: Engineering Immune Cells to Treat Cancer.